Neuca

Neuca Short-term Debt

The Short-Term Debt of Neuca (NEU.WA) as of Nov 1, 2026 is 625.29 M PLN. In the previous year, Short-Term Debt was 296.89 M PLN — a change of 110.61% (higher).

Short-term Debt

625.29 MPLN

YoY

110.61%

Last updated:

Short-Term Debt of Neuca is 2025 625.29 M PLN. Short-Term Debt of Neuca was 2024 296.89 M PLN. It decreases by 110.61% higher compared to the previous year.

The Neuca Short-term Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Short-term Debt
Date
Short-term Debt
Jan 1, 2018
158.75 M PLN
Jan 1, 2019
321.33 M PLN
Jan 1, 2020
85.27 M PLN
Jan 1, 2021
44.02 M PLN
Jan 1, 2022
322.85 M PLN
Jan 1, 2023
383.93 M PLN
Jan 1, 2024
296.89 M PLN
Jan 1, 2025
625.29 M PLN
The Neuca Short-term Debt history
YEARShort-term DebtYoY
625.29 MPLN+110.61%
296.89 MPLN-22.67%
383.93 MPLN+18.92%
322.85 MPLN+633.50%
44.02 MPLN-48.38%
85.27 MPLN-73.46%
321.33 MPLN+102.41%
158.75 MPLN+114.78%
73.91 MPLN-13.37%
85.32 MPLN+22.22%
69.81 MPLN+28.83%
54.19 MPLN—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neuca Stock analysis

What does Neuca do? NEUCA SA generates revenue through the wholesale distribution of pharmaceutical products to pharmacies, leveraging its extensive network in the health market. The company also produces and sells its own branded drugs, supplements, and cosmetics, while offering clinical trials, telemedicine services, and IT solutions tailored for healthcare providers. Its e-commerce platform further supports the healthcare industry by enabling digital transactions for medical products and services. The primary buyers include pharmacies, healthcare institutions, and consumers seeking health-related products through online channels. NEUCA SA's business model integrates multiple revenue streams within the health sector, with a focus on both physical and digital distribution. The firm's own-brand products, such as pharmaceuticals and cosmetics, are sold directly to end-users and retail partners, while its IT solutions and telemedicine services target healthcare organizations. Clinical trials represent another key segment, attracting partnerships with research institutions and pharmaceutical firms. The company's operational scope spans from production to distribution, ensuring a comprehensive approach to healthcare market needs. The company's revenue is driven by its diversified portfolio, including drug distribution, branded product sales, and specialized services like telemedicine and clinical trials. Pharmacies remain the core customer segment for its wholesale operations, while e-commerce and IT solutions cater to a broader audience of healthcare providers and consumers. NEUCA SA's strategic positioning in the health market allows it to capitalize on multiple growth areas without relying on a single revenue source. Neuca is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neuca stock

Short-Term Debt of Neuca is 625.29 M PLN in 2025.

Short-Term Debt of Neuca changed from 296.89 M PLN to 625.29 M PLN, representing a 110.61% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Short-Term Debt Neuca since 2006 – with annual values, charts, and detailed analysis.

Short-term debt represents borrowings due within one year. High short-term debt relative to cash can signal liquidity risk.

Short-Term Debt's PLN is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Short-Term Debt's Neuca historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Neuca

All Key Metrics — Neuca